RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

By Yahoo! Finance | Nov 11, 2024 at 12:24 PM EST

RAPT Therapeutics halts clinical programme for zelnecirnon due to FDA feedback after a patient needed a liver transplant. The company terminated Phase II trials for asthma and atopic dermatitis. They will focus on developing safer CCR4 compounds for inflammatory diseases.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.